Top Markets
Coin of the day
Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc.

ZYNE
Rang in aandelen #26764
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in... Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade cannabidiol expertly crafted into a gel with enhanced skin penetration for topical application. Originally established as AllTranz, Inc., the company adopted its current name, Zynerba Pharmaceuticals, Inc., in August 2014. Founded in 2007, Zynerba Pharmaceuticals maintains its headquarters in Devon, Pennsylvania.
Aandeelprijs
$1.30
Laatst gesynchroniseerd: 2023-10-13
Marktkapitalisatie
$38.02M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Zynerba Pharmaceuticals, Inc. (ZYNE)

Categorie

Dividendrendementgeschiedenis voor Zynerba Pharmaceuticals, Inc. (ZYNE)
Het dividendrendement (TTM) van Zynerba Pharmaceuticals, Inc. (aandelsymbool: ZYNE) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Zynerba Pharmaceuticals, Inc. (ZYNE) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten